Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Historical Acquisition Tree
Alternative names
Key: Revolution Medicines, Inc. (0) Acquired (4)
aumolertinib (3 trials)
Lerociclib (2 trials)
letrozole (femara) (2 trials)
osimertinib (tagrisso) (1 trial)
Key: Revolution Medicines, Inc. (9) Acquired (1)
carboplatin (paraplatin) (1 trial)
cisplatin (platinol) (1 trial)
cobimetinib (cotellic) (1 trial)
fulvestrant (faslodex) (1 trial)
pembrolizumab (keytruda) (2 trials)
pemetrexed (alimta) (1 trial)
rmc-4630 (3 trials)
rmc-6236 (2 trials)
rmc-6291 (2 trials)
sotorasib (LUMAKRAS) (1 trial)
rmc-5552 (2 trials)
rmc-9805 (1 trial)
sar442720 (1 trial)
Key: Revolution Medicines, Inc. (0) Acquired (1)
cs1001 (1 trial)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Trials (16 total)
Trial APIs (18 total)